Cre Deleter

Targeted Transgenic

Cre Deleter Targeted Transgenic Mouse Model

C57BL/6NTac Background

  • Model #
  • Genotype
  • Nomenclature
  • 12524-F
  • 12524-M
  • Ubiquitously active general Cre deleter.
  • This transgene is suspected to be homozygous lethal.
  • Maternal expression of Cre often leads to deletion of loxP flanked target genes in Cre-negative embryos.
  • This model replaces model 6467. Model 12524 is fully congenic on C57BL/6NTac.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:



The Cre Deleter mouse was developed by Artemis Pharmaceuticals (now Taconic). The mutant was created by a targeted mutation knock in of Cre into the Gt(ROSA)26 locus. Cre is expressed under the control of the Gt(ROSA)26Sor gene. Additional sequence elements are adenovirus major late transcript splice acceptor sequence from the intron 1/exon2 boundary situated 5´ and FLP recombinase target (FRT) sequences (Saccharomyces cerevisiae) situated 3´ of Cre. Targeting occurred in C57BL/6N ES cells. The colony is maintained by breeding heterozygotes to wild type C57BL/6NTac mice.





Initial Publication:

Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, Schwarz G, Altmann H, Klewer M, Schoor M, Vonk R, Fritzemeier KH. (2009) GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod 80(1):34-41.

Access to this model requires execution of a Cre Deleter Research Crossbreeding Agreement. Current agreement fees for this model are $1,500/year (€1,125/year) for nonprofit users and $6,000/year (€4,500/year) for for-profit users. Nonprofit transgenic cores should inquire for pricing and terms. Once the agreement is executed, you may order mice for use in crossbreeding. For general inquiries, please contact Taconic Customer Service. To request an agreement, please inquire.